Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

GW Pharma posts more good data from epilepsy trials

In two types of epilepsy, Dravet Syndrome and Lennox-Gastaut Syndrome, Epidiolex reduced the number of seizures compared to the placebo
picture of child
Number of seizures reduced significantly using the drug

Cannabinoid product developer GW Pharmaceuticals PLC (Nasdaq:GWPH) has revealed more good phase III data for its Epidiolex drug for epilepsy sufferers.

In two types of epilepsy, Dravet Syndrome and Lennox-Gastaut Syndrome, Epidiolex reduced the number of seizures compared to the placebo during both the 14 week treatment period and 12 week maintenance period.

 “We are pleased to present key findings from two pivotal Phase 3 studies of Epidiolex and believe these additional positive data reinforce the robust nature of the results achieved in two of the most difficult-to-treat epilepsy patient populations,” said Justin Gover, GW’s chief executive.

He added it was making good progress both towards a new drug admission for Epidiolex in the US and a commercial launch.

Orrin Devinsky, principal investigator of the Dravet syndrome trial, said he and his colleagues were excited by the prospect of prescribing an appropriately standardized and tested pharmaceutical formulation of cannabidiol.” 

“Dravet syndrome and Lennox-Gastaut syndrome are diagnosed in early childhood and represent some of the most difficult types of epilepsy to treat. 

“Nearly all patients continue to have uncontrolled seizures and other medical needs throughout their lifetime,” he said.

Shares rose 5% to US$117.6.

PhilW.jpg


Register here to be notified of future GWP Company articles
View full GWP profile View Profile

GW Pharmaceuticals Timeline

Related Articles

brain-scan.jpg
May 22 2017
In the six months ended March, revenues increased 31% to £2mln
biotechLatest.jpg
March 28 2017
2017 is going to be quite action packed we believe we have positioned the company for when RNA interference transforms from a technology to its promise of a new class of therapeutics - boss Ali Mortazavi.
Proteomics International Laboratories: Access latest PPT from Proactive's CEO Sessions
April 13 2017
Richard Lipscombe talked revenue generation and growth path with investors.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use